4881.T stock jumped 23.08% to JPY 112.00 in after-hours trading on 05 Mar 2026, driven by heavy volume of 7,725,000.00 shares versus an average of 931,878.00. The move pushed the intraday high to JPY 112.00 from an open of JPY 89.00, and it occurred on the JPX market in Japan. FunPep Company Limited is a small-cap biotech with a pipeline that includes SR-0379 and FPP003, which investors often track for trial updates. We look at why volume spiked, the company’s valuation, technical setup, and what Meyka AI’s grade and forecast imply for traders.

4881.T stock: volume surge and price action

Today FunPep (4881.T) recorded a 23.08% one-day gain to JPY 112.00 on unusually high volume of 7,725,000.00. The relative volume at 1.35 and average daily volume of 931,878.00 show significant retail or event-driven flow. There was no public SEC-style filing at time of this note, so the spike likely reflects investor reaction to pipeline chatter or block trades rather than a confirmed earnings release. Check the company site for company announcements: FunPep site.

4881.T stock: valuation and financial snapshot

FunPep trades at PE -1.95 with EPS -42.10 and market cap JPY 3,326,230,616.00. Cash per share stands at JPY 44.54 and book value per share at JPY 36.88, giving a price-to-book of 2.22. Revenue per share is negligible at 0.01, while R&D to revenue reads 4,127.47%, reflecting a pure development-stage biotech. The firm reports a current ratio 3.74, so near-term liquidity appears adequate for ongoing trials.

4881.T stock: technicals and trading indicators

Technical indicators show mixed momentum for 4881.T stock. RSI is 41.13, MACD histogram is -1.00, and ADX is 29.83 suggesting a strong short-term trend. Bollinger bands range from JPY 80.05 to JPY 103.75, with the price now above the middle band at JPY 91.90. Traders should note ATR 5.74 and on-balance volume at 17,992,600.00, indicating real buying pressure today.

4881.T stock: Meyka AI rates 4881.T with a score out of 100

Meyka AI rates 4881.T with a score out of 100: 67.39 which maps to Grade B and a HOLD suggestion. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecast data. The platform flags strong cash buffers but negative earnings and high R&D intensity as central drivers of the moderate score. These grades are informational and not financial advice.

4881.T stock: catalysts and risks

Key catalysts for 4881.T stock include clinical readouts for SR-0379 and Phase II updates for FPP003, plus regulatory news in Japan and Australia. The next formal earnings announcement is scheduled for 2026-05-18, which could reprice the stock. Main risks are persistent net losses, negative margins, and the sector peer PE average of 23.61 which contrasts with FunPep’s negative PE. R&D concentration and trial binary risk make volatility likely.

4881.T stock: scenario price targets and forecast comparison

Meyka AI’s model projects monthly JPY 67.31, quarterly JPY 57.17, and yearly JPY 50.53, versus the current price JPY 112.00. That implies model-based downside of -39.88% at monthly, -48.94% at quarterly, and -54.84% at yearly horizons. For bull-case traders, a near-term retest of the year high JPY 143.00 remains possible on positive trial news, but probabilities are lower than downside scenarios. Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways on 4881.T stock: the after-hours jump to JPY 112.00 on 05 Mar 2026 came with a large volume spike of 7,725,000.00 shares, signalling event-driven interest. Fundamentals show heavy R&D spending, negative EPS (-42.10) and a price-to-book of 2.22, while liquidity metrics like current ratio 3.74 support near-term funding. Meyka AI’s forecast model projects JPY 50.53 for the year, implying -54.84% from today’s price, and suggests downside risk unless clinical or corporate news changes the outlook. Traders and investors should weigh high binary clinical risk against cash reserves and sector comparables in Healthcare on JPX. For fast-moving intraday traders, watch volume, news wires, and the upcoming 2026-05-18 earnings date. Remember, Meyka AI is an AI-powered market analysis platform and forecasts are model-based projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.